Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation

Franck F. Rahaghi1, Jeremy P. Feldman2, Roblee P. Allen3, Victor Tapson4, Zeenat Safdar5, Vijay P. Balasubramanian6, Shelley Shapiro7, Michael A. Mathier8, Jean M. Elwing9, Murali M. Chakinala10 and R. James White11

1Pulmonary Hypertension Clinic, Advanced Lung Disease Clinic, Weston, FL, USA; 2Arizona Pulmonary Specialists Ltd, AZ, USA; 3U.C. Davis Health System, Sacramento, CA, USA; 4Cedars-Sinai Medical Center, Los Angeles, CA, USA; 5Houston Methodist, Houston, TX, USA; 6UCSF Fresno, Fresno, CA, USA; 7David Geffen UCLA School of Medicine, Los Angeles, CA, USA; 8University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 9University of Cincinnati, Cincinnati, OH, USA; 10Washington University, St. Louis, MO, USA; 11University of Rochester Medical Center, Rochester, NY

Abstract
Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil. Despite its oral route of delivery, use of the drug is challenging because of the requirement for careful titration and management of drug-related adverse effects. We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil. Following a methodology commonly used in business and social sciences (the ‘Delphi Process’), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert. The set of ‘best practice’ statements was circulated to nine other Freedom trial investigators. Their comments were incorporated into the document as new line items for further vote and comment. The subsequent document was put to vote line by line (scale of −5 to +5) and a final statement was drafted. Consensus recommendations include initial therapy with 0.125 mg for treatment naïve patients, three times daily dosing, aggressive use of antidiarrheal medication, and a strong preference for use of the drug in combination with other approved PAH therapies. This process was particularly valuable in providing guidance for the management of adverse events (where essentially no data is available). The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.

Keywords
oral treprostinil, pulmonary arterial hypertension, pulmonary delphi studies, drug side effects

Date received: 26 July 2016; accepted: 7 November 2016

Pulmonary Circulation 2017; 7(1) 167–174
DOI: 10.1086/690109

Best practices in the use of a specific drug are often perfected over time. This is particularly true in rare diseases such as pulmonary arterial hypertension (PAH) and even more so for drugs that require individual titration. Learning that accrues over time is, by definition, not reflected in the initial pivotal clinical trials for drug registration. Open label extension trials and early post-marketing experience often add substantially to our overall knowledge of the drug and thus lead to best practices that are not reflected in the official prescribing information. Subcutaneous treprostinil is an example of this limitation: the full prescribing information still reflects the dosing from the initial trial reported by Simonneau in 2002,1 while practical suggestions published recently offer very different ideas for the use of the drug.2,3

Corresponding author:
Franck F. Rahaghi, Advanced Lung Disease Clinic, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA.
Email: RAHAGHF@ccf.org

© 2017 by Pulmonary Vascular Research Institute.
Reprints and permissions: sagepub.co.uk/journalsPermissions.nav
journals.sagepub.com/home/pul
In addition, adverse effects of trial medications are meticulously collected to assure safety for those exposed to an investigational drug. Researchers generally manage the side effects without direction from the clinical trial organizers. Their approach to adverse effect management is not systematically collected and therefore not reported and not available to less experienced clinicians that might consider using the drug.

Oral treprostinil (Orenitram®) was FDA approved in December 2013 for use as oral monotherapy. The initial trials commenced in 2006 and thus the accumulated investigator experience is much richer than disclosed in the package insert. The package insert includes little or no guidance on the management of common and important adverse effects, and even the most basic of prescribing information (twice or three times daily) is left to the prescriber with little direction. This leaves physicians who manage pulmonary hypertension (PH) but did not participate in the oral treprostinil (Freedom) studies with relatively little guidance in the practical use of the drug.

The Delphi methodology dates back to the 1950s and was developed to create consensus in social science topics. The methodology is particularly relevant when there is real knowledge available on a particular topic, but definitive experiments to prove the point are lacking. The Delphi approach involves digestion of the existing data and practices by subject matter experts, followed by successive refinement and consensus building among a larger group of experts. It seems particularly well-suited to a rare disease like PAH where significant advances in the use of a medication occur well after drug approval, often in trials not rigorous enough to influence changes to the labeled prescribing information. The ongoing, long-term Freedom-EV study will yield important information about three times daily dosing of oral treprostinil, effective doses, and appropriate titration strategies. However, until that data are available, we believe that the current approach has provided useful information which reflects the collective prescription and management pattern of experts with considerable experience. The first two authors (FFR and JF) created the initial document based on available evidence and the oral treprostinil package insert. The document was a topic-generated spreadsheet of 39 statements. This initial document was circulated to the participant experts who commented on each statement; they were also invited to make additional relevant statements. This resulted in the addition of 41 new statements or pieces of advice (total of 80). Each commenting author added an average of six statements (some were similar, hence only a total of 41 new lines were added). In the next iteration, this new, larger document was presented to the group for a numeric vote on a scale of strongly disagree (−5) to strongly agree (+5). We chose an average score of 2.5 as sufficient to be considered consensus for the major recommendations. The full set is made available so the reader can make their own judgment in terms of the strength of the recommendation. We did not include two statements with a score ≥2.5 as major recommendations because the standard deviation was 2.5 or greater, indicating a lack of consensus (a mix of positive and negative scores). This final iteration of statements was reviewed by all participants for final acknowledgement and comments. The entirety of the final line item spreadsheet is presented here as Tables 2 and 3, divided according to dosing and adverse

### Methods

We used a modified Delphi methodology to reach a consensus statement. Delphi methodology has been previously reviewed. The basic method as described by Delbecq et al. is as follows: 1

1. Develop initial questionnaire and distribute it to the panel.
2. Panelists independently generate their ideas in answer to the questionnaire and return it.
3. The moderator summarizes the responses to the first questionnaire and develops a feedback report along with the second set of questionnaires for the panelists.
4. Having received the feedback report, panelists independently evaluate earlier responses and independently vote on the second questionnaire.
5. The moderator develops a final summary and feedback report to the group and decision-makers.

Following Delphi guidelines, the experts were encouraged to include comment and literature as they saw fit, for the benefit of the group. The literature and the aggregate responses were included anonymously. Comments were encouraged about the validity, specificity, and content of the items under consideration, and incorporated verbatim and anonymously in the tabulated statement. Anonymity is deemed essential in Delphi methodology to prevent bias by influential clinicians and to reduce the pressure towards conformity.

The first author (FFR) invited 11 other US investigators with high enrolment in the various Freedom trials, of which ten responded. Table 1 displays the characteristics of the experts. The first two authors (FFR and JF) created the initial document based on available evidence and the oral treprostinil package insert. The document was a topic-generated spreadsheet of 39 statements. This initial document was circulated to the participant experts who commented on each statement; they were also invited to make additional relevant statements. This resulted in the addition of 41 new statements or pieces of advice (total of 80). Each commenting author added an average of six statements (some were similar, hence only a total of 41 new lines were added). In the next iteration, this new, larger document was presented to the group for a numeric vote on a scale of strongly disagree (−5) to strongly agree (+5). We chose an average score of 2.5 as sufficient to be considered consensus for the major recommendations. The full set is made available so the reader can make their own judgment in terms of the strength of the recommendation. We did not include two statements with a score ≥2.5 as major recommendations because the standard deviation was 2.5 or greater, indicating a lack of consensus (a mix of positive and negative scores). This final iteration of statements was reviewed by all participants for final acknowledgement and comments. The entirety of the final line item spreadsheet is presented here as Tables 2 and 3, divided according to dosing and adverse

### Table 1. Characteristics of participants.

| Practice setting | Participants (n) |
|------------------|------------------|
| Private          | 1                |
| Teaching         | 2                |
| Academic         | 8                |

| Centers (n) | Total patient experience |
|-------------|--------------------------|
| 11          | 206 patients: average, 18.7; median, 20; range, 5–34 |
### Table 2. Dosing recommendations.

| Dosing | Score | SD | Range |
|--------|-------|----|-------|
| Three times daily dosing is preferred to two times a day | 4.27 | 1.49 | 0 to 5 |
| Three times daily dosing is less dependent on food intake | 1.91 | 2.81 | -5 to 5 |

#### Starting Dose In Treprostinil Naive Patients

| Starting dose 0.125 in patients with relative hypotension, low tolerance for side effects, or <60kg | 3.55 | 1.69 | -3 to 5 |
| Either 0.125 or 0.25 mg is acceptable<sup>a</sup> | 3.18 | 1.54 | -1 to 5 |
| Starting dose: 0.25 mg<sup>b</sup> | 2.27 | 2.65 | -3 to 5 |
| Starting dose of 0.125 is preferable to higher starting doses | 1.82 | 2.86 | -2 to 5 |

#### Titration In Treprostinil Naive Patients

| Space doses at least 5 hours apart, ideally 6–8 hours apart during awake hours | 4.36 | 0.81 | -4 to 5 |
| Titrator by 0.125 | 2.91 | 1.70 | 1 to 4 |
| Titrator by 0.25 mg | 2.55 | 3.08 | -4 to 5 |
| Consider first up-titrating with the evening dose | 2.36 | 1.91 | 0 to 5 |
| Not more than every 3 to 4 days as tolerated | 2.09 | 3.21 | -4 to 5 |
| Titrator weekly for practical reasons | 1.73 | 2.80 | -4 to 5 |
| Attempt to dose q12 instead of BID if BID dosing is chosen | 1.55 | 3.47 | -3 to 5 |
| Consider step dosing, increasing first the evening dose, then the afternoon dose and then the morning dose (comes to every three days) | 1.09 | 2.81 | 0 to 5 |
| Can be titrated as fast as 2 days | 1.00 | 3.79 | -5 to 5 |
| Titrator By 0.5 mg | -0.91 | 2.81 | -5 to -4 |

#### Desired Dose/Maximum Dose

| The Maximum dose is determined by tolerability | 4.36 | 1.03 | 2 to 5 |
| Consider setting titration dose goals | 3.91 | 1.30 | 1 to 5 |
| Three month goal of approximately 4 mg tid | 4.09 | 0.70 | 3 to 5 |
| Dose should be revisited at least annually for clinical efficacy | 3.82 | 1.40 | 1 to 5 |
| Consider 6 month target 6 mg tid | 3.18 | 1.54 | 0 to 5 |
| Consider 12 month target 8 mg tid | 2.82 | 1.25 | 0 to 5 |
| The Minimal dose is determined by Clinical Improvement | 2.73 | 2.80 | -3 to 5 |
| Orenitram at 1 mg tid equivalent to Remodulin 6ng/kg/min for a 70 kg patient (8mg tid for 50 ng/kg/min) | 2.36 | 2.42 | -3 to 5 |
| Maximum doses studied were 12 mg BID in the 12-week blinded study is a maximum dose to consider | 0.73 | 3.10 | -5 to 4 |

#### Avoid Abrupt Discontinuation

| Consider a lower resumption dose and a rapid up-titratio after several missed doses | 3.82 | 0.75 | 3 to 5 |
| Interruptions of more than 1–2 doses can lead to severe rebound side effects, if same dose is reinstated | 3.18 | 2.23 | -2 to 5 |

#### Use as first line therapy

| In selected and well compensated patients able to weather the few months before an effective dose is achieved, oral treprostinil can be used as monotherapy | -0.55 | 3.44 | -5 to 5 |
| Oral treprostinil can be used as first line therapy | -0.82 | 3.41 | -3 to 5 |

#### Use as add-on therapy

| No adjustment in Bosentan and Sildenafil with the addition of Oral Trep | 4.36 | 0.67 | 3 to 5 |
| Possible potentiation of HA with PDE5 inhibitors | 3.55 | 0.93 | 3 to 5 |
| Oral Treprostinil should be used as add-on therapy | 2.73 | 1.39 | 1 to 5 |

#### Candidates for transition from IV/ SQ to Oral Treprostinil

| With presence of another oral medication | 3.82 | 1.08 | 2 to 5 |
| In carefully selected patient with durable response & excellent hemodynamics | 2.91 | 1.70 | 1 to 5 |
| And on parenteral doses 25–75 ng/kg/min | 1.91 | 3.33 | -5 to 5 |
Table 3. Adverse event management.

| Side effect management                  | Score | SD   | Range  |
|-----------------------------------------|-------|------|--------|
| **Diarrhea**                            |       |      |        |
| Dicycloverine (Lomotil<sup>TM</sup>)    | 3.91  | 1.51 | 0 to 5 |
| Loperamide (Imodium<sup>TM</sup>)       | 3.55  | 2.02 | 0 to 5 |
| Add fiber to bulked stool, if very loose| 1.82  | 1.56 | 0 to 5 |
| Dicyclomine (Bentyl<sup>TM</sup>)/ antispasmodics | 1.55  | 3.14 | −3 to 5 |
| **Nausea**                              |       |      |        |
| First Line                              |       |      |        |
| Take with food                          | 4.64  | 0.67 | 0 to 5 |
| Ondansetron (Zofran<sup>TM</sup>)       | 4.27  | 1.01 | 2 to 5 |
| Proton Pump Inhibitors                  | 2.09  | 2.43 | 0 to 5 |
| Promethazine (Phenergan<sup>TM</sup>)   | 0.09  | 2.95 | −5 to 5 |
| Second Line                             |       |      |        |
| Prochlorperazine (Compazine<sup>TM</sup>-Oral/ Suppository) | 2.45  | 1.81 | −3 to 5 |
| Proton Pump Inhibitors                  | 2.09  | 2.43 | −3 to 5 |
| Oral Promethazine (Phenergan<sup>TM</sup>) | 1.82  | 2.64 | −3 to 5 |
| Metoclopramide (Reglan<sup>TM</sup>)    | 0.73  | 2.53 | −3 to 4 |
| **Head Ache**                           |       |      |        |
| First Line                              |       |      |        |
| Acetaminophen                           | 4.45  | 0.82 | 3 to 5 |
| Second Line                             |       |      |        |
| Tramadol (Ultram<sup>TM</sup>)          | 2.82  | 1.10 | 2 to 5 |
| Opiates in the most severe cases        | 2.73  | 1.33 | 1 to 5 |
| Gabapentin (Neurontin<sup>TM</sup>)     | 2.36  | 2.07 | 0 to 5 |
| Ibuprofen                               | 1.09  | 3.67 | −3 to 5 |
| Naproxen                                | 0.82  | 3.81 | −5 to 5 |
| Prescription Non-Opioids NSAIDs (Diclofenac, Meloxicam, Lodine, Indocin, etc.) | −0.36 | 2.92 | −5 to 5 |
| Amitriptyline (Elavil<sup>TM</sup>)     | −0.36 | 2.73 | −5 to 5 |
| **Flushing**                            |       |      |        |
| Reassurance                             | 4.09  | 0.71 | 3 to 5 |
| Slow down up-titration only if absolutely needed | 2.64  | 2.23 | −3 to 5 |

*Statements based on available evidence.
SD, standard deviation.
events management. Major recommendations (consensus as described above) are shaded.

Results

The final product of our modified Delphi process is presented as Table 2 for dosing recommendations and Table 3 for adverse events management. Those recommendations which are grounded in the package insert or available literature (present in the initial list) are identified with asterisks. The consensus statements (see the “Methods” section) are highlighted. There were other statements with favorable recommendations but some significant negative votes resulted in a large standard deviation which precluded a consensus recommendation.

The group strongly recommended three times a day (t.i.d.) dosing versus twice a day (b.i.d.) dosing (Table 2). As for the starting dose, both 0.125 and 0.25 mg were judged acceptable (but not 0.5 mg) with a suggestion to use 0.125 mg in smaller patients and in those with low blood pressure or low tolerance to side effects. Slow titration was preferred overall with 0.125 dose increments. Even though the 0.25 mg dose had a score of 2.54, there were a few strong votes against increasing the dose by 0.25 mg (standard deviation > 2.5). Investigators preferred that patients space the medication throughout the day with doses 6–8 h apart; they strongly agreed that doses be at least 5 h apart. Increasing just one of the doses (the evening dose) before increasing the other doses almost achieved “consensus.”

Investigators agreed that the doses achieved in the placebo-controlled trials were insufficient and demonstrated remarkable agreement on goal setting. The group set target doses of 4 mg t.i.d. at three months, 6 mg t.i.d. at 6 months, and 8 mg t.i.d. at one year. The group agreed that annual reassessments of dosing and efficacy were necessary at a minimum, and that the maximum dose would be dictated by side effects. Interruptions must be avoided, and if multiple doses (> 2) are missed, investigators recommend resuming at a lower dose with rapid re-titration. In general, the group recommended that the drug be used in combination with other PAH-specific therapies. The group agreed that the drug should not be used as first-line therapy. The original combination studies were launched when only sildenafil and bosentan were available (2006); the package insert specifically states that dose adjustments for sildenafil and bosentan are not necessary, and the investigators agreed with that statement.

Investigators strongly agree that headache is more common for patients when oral treprostinil is added to a background phosphodiesterase-5 inhibitor (PDE5-I).

The package insert indicates that oral treprostinil may be useful for patients who are already using parenteral or inhaled treprostinil and now includes data from the recently published parenteral to oral transition study delineating a methodology for transition.24 Our Delphi process concluded that only carefully selected parenteral treprostinil patients with a durable response to therapy and excellent hemodynamics were reasonable candidates for transition to oral treprostinil. The group strongly recommended a 2–5-day

Table 3. Continued

| Side effect management                        | Score | SD    | Range |
|------------------------------------------------|-------|-------|-------|
| Jaw Pain                                       |       |       |       |
| No measures are necessary                      | 3.55  | 1.32  | 1 to 5|
| Reassure patient that this would get better with time | 2.73  | 1.16  | 3 to 5|
| Cracker before meals                           | 1.55  | 1.64  | 0 to 3|
| Chew gum                                       | 1.55  | 1.64  | 0 to 4|
| Dizziness                                      |       |       |       |
| Decrease blood pressure medications            | 4.18  | 0.70  | 3 to 5|
| Manage under-hydration or over-diuresis        | 3.82  | 1.32  | 1 to 5|
| Close monitoring of blood pressure             | 3.64  | 1.70  | 0 to 5|
| Decrease oral treprostinil dose                | 3.36  | 0.95  | 3 to 5|
| Hypotension                                    |       |       |       |
| Stop or decrease blood pressure medications    | 4.18  | 0.70  | 3 to 5|
| Manage under-hydration or over-diuresis        | 3.73  | 1.37  | 1 to 5|
| Proamatine (Midrodrine™) to facilitate hemodialysis | 2.45  | 1.34  | 1 to 5|
| If Low systemic vascular resistance suspected, Proamatine (Midrodrine™) 10 mg tid | 1.64  | 2.66  | −5 to 5|
| Pain in the extremity                          |       |       |       |
| Gabapentin(Neurotin™)                          | 3.45  | 1.55  | 0 to 5|
| Screen for Iron deficiency (restless legs)     | 2.45  | 2.21  | 0 to 5|
| Acetaminophen                                  | 2.09  | 2.31  | −2 to 5|
| Duloxetine (Cymbalta™)                         | 1.55  | 1.83  | −2 to 4|

SD, standard deviation.
transition in hospital and also were near unanimous that these participants should be using at least one additional oral PAH-specific therapy to insure disease stability during the transition. There was less consensus about the method for transitioning from inhaled treprostinil as there are currently fewer data.

Patients with end-stage renal disease on hemodialysis (and without PAH) have been formally studied and the package insert indicates that no dose adjustments are necessary. Our experts agreed with that but suggested that dialysis patients may require a slower up-titration with attention to hypotension at hemodialysis. The package insert identifies drug–drug interactions with HIV medications but only one of our experts commented on this as a problem in experience.

With regard to side effect management (Table 3), the investigators reached consensus about Loperamide (ImodiumTM) and Diphenoxylate/Atropine (LomotilTM) to ameliorate diarrhea. To alleviate nausea, investigators strongly recommended taking the drug with food as well as using Ondansetron (ZofranTM). It is worth noting that specific food choices or calorie counts are not mandatory for t.i.d. dosing whereas specific calorie counts and fat content were protocol-required for b.i.d. dosing in the trials.

Promethazine was rated as a second-line nausea agent. Acetaminophen was preferred for headache, tramadol (UltramTM) for more significant pain, and opiates only in the most severe cases. Amitriptyline and non-steroidal anti-inflammatory agents (NSAIDs) were not recommended; however, there was a great deal of disagreement here and at least some investigators thought that these were helpful.

Reassurance was suggested for jaw pain and flushing. In response to dizziness or overt hypotension, the investigators strongly recommended that physicians reduce or eliminate other medications for systemic hypertension. They also suggested close monitoring of blood pressure and oral treprostinil dose reduction. Investigators strongly recommended gabapentin for pain in the extremities and also suggested screening for iron deficiency to address restless legs as a possible contributor.

Discussion

The purpose of this paper was to give practical guidance about using oral treprostinil with specific regard to dosing and management of adverse effects. We used a well-established method, the Delphi process, to build consensus among a group of US investigators who had substantial oral treprostinil experience. The consensus statements in Tables 2 and 3 with the final scores were generated with an initial draft and two iterations (voting at second iteration). We highlighted as “consensus” any statement that achieved an average score above 2.5 as long as the standard deviation was less than 2.5.

The strongest consensus was built around three times daily dosing with a strong emphasis on dividing the doses evenly over waking hours. In the experience of this group, the drug is best tolerated when dosed every 7–8 h. B.i.d. dosing causes wide swings in blood treprostinil levels with a large peak:trough ratio and a prolonged time at the end of the dosing period when blood levels are quite low.

Data presented in abstract form confirm that trough blood levels were higher in a group of 13 participants who switched from b.i.d. to t.i.d. dosing; adverse events in this group were less intense during the t.i.d data collection phase suggesting that the hypothesis of peak:trough levels driving adverse events is reasonable. Similarly, in the recent report of participants transitioning from parenteral to oral treprostinil, participants using the t.i.d. drug had a lower peak:trough ratio and achieved higher daily doses of oral treprostinil with apparently better drug tolerance as compared to those using the b.i.d. drug.

The group generally favored a starting dose of 0.125 mg and titration by 0.125 mg. Some investigators have found that it is helpful to increase the evening dose first (to allow overnight acclimation). Others have found that spacing the titration out even further is advantageous: a “stair step” process in which the evening dose is increased on one day and then the afternoon dose the next titration day and finally the morning dose (possibly a Monday–Wednesday–Friday strategy for simplicity). Slower strategies may be especially helpful for smaller patients or those who get “stuck” at a dose because of headache, nausea, or diarrhea with dose increases. No consensus was reached as to the number days or frequency of up-titration. The variety of opinions are reflected in the statements that did not reach consensus in Table 2, including the package insert suggestion of not up-titrating more than twice a week. More research is necessary to clarify optimal titration strategies, as reflected in the lack of consensus around dosing strategies.

There is little literature available as to the place of oral treprostinil in the pantheon of medications now available to use for PAH. Aside from the preference to not use the drug as a first-line agent, the process did not result in statements attempting to define the kind of patient that would benefit from oral treprostinil. There is now recently published evidence supporting the group consensus around combination/second-line therapy.

A key goal of our effort was to outline expert opinions on the management of adverse effects because the primary publications and package insert do not generally make statements about management approaches. Table 3 makes very specific suggestions and shows the degree to which the group agreed on any given strategy. The group strongly recommended aggressive treatment of nausea with Ondansetron, diarrhea with Loperamide, and headache with analgesics. The list generated by the Delphi process is a distillation of what the experts are practically using to address adverse events. The specific adverse events may have many other remedies explored in other disease states. We have included
in the references reviews of current general management of diarrhea,27–29 nausea,30–32 and headache33–36 for readers’ benefit.

There are important limitations to this methodology. A clear advantage was the electronic nature of data collection and dissemination, which minimizes financial constraints and need for support. The anonymous nature promotes the free sharing of opinions and ideas, preventing a dominant leader from dismissing less popular concepts. In contrast, a face-to-face process allows individuals to explain and defend ideas, which might improve the quality of some recommendations. Similarly, the process gives equal voice and weight to the most and least experienced; this has the advantage that a variety of opinions are expressed and the disadvantage that very knowledgeable opinions might be “out-voted” in the process. For example, the need for dose adjustment among those taking certain HIV medicines is near certain (and is described in the label), but the panel did not recognize this fact.

An additional limitation has to do with the selection of experts. We explicitly limited our work team to those in the United States with substantial experience in the Freedom studies. The number of investigators was also limited to make a manageable process. Table 1 demonstrates that this group had a substantial composite research subject experience, but investigators outside the US are not represented here.

In conclusion, we used the Delphi methodology to assist practicing physicians in the use of a newly approved drug. The information in Tables 2 and 3 are intended as a practical supplement to the data reported in the primary trials and the information in the package insert.

Acknowledgments

FFR would like to thank the Hamilton Family Fund for support of scholarly activities at the Cleveland Clinic Florida.

Conflict of interest

VT, FFR, ZS, RPA, and JF serve or served in the past on the speaker s bureau of United Therapeutics (makers of Oral Treprostinil). VT, FFR, ZS, RPA, MMC, JME, and JF served as United Therapeutics consultants. RJW serves as a consultant to UT but all compensation goes to the University of Rochester.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.

2. White RJ, Levin Y, Wessman K, et al. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Palm Circ 2013; 3: 611–621.

3. Mathier MA, McDevitt S and Sagar R. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. J Heart Lung Transplant 2010; 29: 1210–1217.

4. Haines S, Baker T and Donaldson M. Development of a psychological performance assessment checklist for athletes who sustained a lower extremity injury in preparation for return to sport: a delphi study. Int J Sports Phys Ther 2013; 8: 44–53.

5. Li Y, Ehiri J, Hu D, et al. Framework of behavioral indicators for outcome evaluation of TB health promotion: a Delphi study of TB suspects and TB patients. BMC Infect Dis 2014; 14: 268.

6. Mansell G, Shapley M, van der Windt D, et al. Critical items for assessing risk of lung and colorectal cancer in primary care: a Delphi study. Br J Gen Pract 2014; 64: e509–e515.

7. Phillips AC, Lewis LK, McEvoy MP, et al. A Delphi survey to determine how educational interventions for evidence-based practice should be reported: stage 2 of the development of a reporting guideline. BMC Med Educ 2014; 14: 159.

8. Phillips AC, Lewis LK, McEvoy MP, et al. Protocol for development of the guideline for reporting evidence based practice educational interventions and teaching (GREET) statement. BMC Med Educ 2013; 13: 9.

9. Pietersma S, de VM and van den Akker-van Marle ME. Domains of quality of life: results of a three-stage Delphi consensus procedure among patients, family of patients, clinicians, scientists and the general public. Qual Life Res 2014: 23; 1543–1556.

10. Schutt AC, Bullington WM and Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104: 717–723.

11. Linstone HA and Turoff M. The Delphi method techniques and applications. Reading, MA: Addison-Wesley Pub. Co., Advanced Book Program, 1975.

12. Hsu C-C and Sandford BA. The Delphi Technique: Making Sense of Consensus. Practical Assessment Research & Evaluation 2007; 12: 1–8.

13. Hasson F, Keeney S and McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008–1015.

14. de Meyrick J. The Delphi method and health research. Health Educ 2003; 103: 7–16.

15. Lim A, Wang-Smith L, Kates J, et al. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers. J Clin Pharm Ther 2013; 38: 450–455.

16. Gotzkowsky SK, Kumar P, Mottola D, et al. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. J Cardiovasc Pharmacol 2013; 61: 444–451.

17. White RJ, Torres F, Allen R, et al. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2013; 61: 474–481.

18. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127: 624–633.

19. Jenkins A, Wang-Smith L, Marbury T, et al. Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal
20. Gotzkowsky SK, Dingemanse J, Lai A, et al. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. *J Clin Pharmacol* 2010; 50: 829–834.

21. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. *Chest* 2012; 142: 1383–1390.

22. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. *Chest* 2013; 144: 952–958.

23. Peterson L, Marbury T, Marier J, et al. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. *J Clin Pharm Ther* 2013; 38: 518–523.

24. Chakinala MM, Feldman JP, Rischar F, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. *J Heart Lung Transplant* 2016; DOI:10.1016/j.healun.2016.06.019.

25. White RJ, Frutiger K, Theuer A, et al. A pharmacokinetic and tolerability comparison in subjects transitioning from twice daily to three times daily dosing of oral treprostinil. *Chest* 2014; 146(4_MeetingAbstracts): 865A.

26. White RJ and Rao Y. Novel analysis of the oral treprostinil combination therapy trial data. *Am J Respir Crit Care Med* 2016; 193: 1434–1436.

27. Lee KJ. Pharmacologic agents for chronic diarrhea. *Intest Res* 2015; 13: 306–312.

28. Li Z and Vaziri H. Treatment of chronic diarrhoea. *Best Pract Res Clin Gastroenterol* 2012; 26: 677–687.

29. Schiller LR, Pardi DS and Sellin JH. Chronic diarrhea: diagnosis and management. *Clin Gastroenterol Hepatol* 2016; DOI:10.1016/j.cgh.2016.07.028.

30. Natale JJ. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. *Hosp Pract (1995)* 2015; 43: 226–234.

31. Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. *Biomed Res Int* 2015; 2015: 595894.

32. Schwartzberg L. Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. *Expert Rev Pharmacoecon Outcomes Res* 2014; 14: 825–834.

33. Bendtsen L. Treatment guidelines: implications for community-based headache treatment. *Int J Clin Pract Suppl* 2015; 182: 13–16.

34. Carville S, Padhi S, Reason T, et al. Diagnosis and management of headaches in young people and adults: summary of NICE guidance. *BMJ* 2012; 345: e5765.

35. Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: The American Headache Society Evidence-Based Guidelines. *Headache* 2016; 56: 1093–1106.

36. Thornby KA, Henneman A and Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. *Ann Pharmacother* 2015; 49: 715–726.